Related Experiment Videos
Low-dose steroid therapy does not affect hemodynamic response in septic shock patients
Joan M Raurich1, Juan A Llompart-Pou, Jordi Ibáñez
1Servicio de Medicina Intensiva, Hospital Universitario Son Dureta, 07014 Palma de Mallorca, Spain. jmraurich@hsd.es
Journal of Critical Care
|December 19, 2007
Summary
Low-dose steroid therapy (LDST) did not shorten shock duration or reduce mortality in septic shock patients. This retrospective study found no significant benefit of LDST in critical care settings.
Area of Science:
- Critical Care Medicine
- Endocrinology
- Infectious Diseases
Background:
- Low-dose steroid therapy (LDST) has been proposed to improve outcomes in septic shock.
- Previous studies suggest LDST may reduce shock duration and mortality.
- However, the efficacy of LDST in septic shock remains debated.
Purpose of the Study:
- To evaluate the impact of LDST on time to shock reversal.
- To assess the effect of LDST on inhospital mortality in septic shock patients.
Main Methods:
- Retrospective study of 203 septic shock patients.
- Propensity score analysis used to adjust for baseline characteristics.
- Evaluated time to shock reversal and inhospital mortality.
Main Results:
- LDST was not associated with a reduced time to shock reversal (HR 1.15; 95% CI 0.71-1.86).
- Inhospital mortality was 62% in the steroid group vs. 52% in the control group (P = .84).
- Propensity score analysis showed no significant difference in mortality between groups.
Conclusions:
- LDST was not associated with improved outcomes in this septic shock cohort.
- Age, SOFA score, and inadequate antibiotics predicted mortality.
- Further research may be needed to clarify the role of LDST in septic shock.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:21Dose Response Curve: Conventional Versus Nonmonotonic
The correlation between a drug's dosage and its impact on a biological system is a cornerstone of pharmacology and toxicology. Conventional dose–response curves, which include graded and quantal relationships, are key to this understanding. Graded dose–response curves depict the spectrum of a biological reaction to different doses within an individual, indicating that as the drug dosage increases, so does the intensity of the response. On the other hand, quantal dose–response relationships...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:21Factors Affecting Drug Response: Overview
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...